Evidence map›Paper›PMID 32429600›Full record

ReviewToxins2020

FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia.

Lauren L Spiegel, Jill L Ostrem, Ian O Bledsoe

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Toxins, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. XeominToxins · 2023
    Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lauren L SpiegelMovement Disorders and Neuromodulation Center, Department of Neurology, University of California, San Francisco, CA 94115, USA.
Jill L OstremMovement Disorders and Neuromodulation Center, Department of Neurology, University of California, San Francisco, CA 94115, USA.
Ian O BledsoeMovement Disorders and Neuromodulation Center, Department of Neurology, University of California, San Francisco, CA 94115, USA.ORCID 0000-0001-8885-8148

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2016, the American Academy of Neurology (AAN) published practice guidelines for botulinum toxin (BoNT) in the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. This article, focusing on dystonia, provides context for these guidelines through literature review. Studies that led to Food and Drug Administration (FDA) approval of each toxin for dystonia indications are reviewed, in addition to several studies highlighted by the AAN guidelines. The AAN guidelines for the use of BoNT in dystonia are compared with those of the European Federation of the Neurological Societies (EFNS), and common off-label uses for BoNT in dystonia are discussed. Toxins not currently FDA-approved for the treatment of dystonia are additionally reviewed. In the future, additional toxins may become FDA-approved for the treatment of dystonia given expanding research in this area.

Indexed as

Drug ApprovalAcetylcholine Release InhibitorsBotulinum ToxinsConsensusDrug CompoundingDystoniaHumansOff-Label UsePractice Guidelines as TopicUnited StatesUnited States Food and Drug AdministrationAcetylcholine Release InhibitorsBotulinum Toxinsblepharospasmbotulinum toxincervical dystoniadystoniaFDA

Identifiers

PMID32429600
PMCPMC7290737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.